Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years

BACKGROUND:CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection. METHODS:Phase I, 24-week safety and pharmacokinetic (PK) study of EFV in HIV-infected children age...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2019-08, Vol.81 (4), p.473-480
Hauptverfasser:	Bwakura Dangarembizi, Mutsa, Samson, Pearl, Capparelli, Edmund V, Moore, Carolyn Bolton, Jean-Philippe, Patrick, Spector, Stephen A, Chakhtoura, Nahida, Benns, Alex, Zimmer, Bonnie, Purdue, Lynette, Jackson, Chivon, Wallis, Carole, Libous, Jennifer L, Chadwick, Ellen G
Format:	Artikel
Sprache:	eng
Schlagworte:	Africa AIDS/HIV Antiretroviral drugs Benzoxazines - administration & dosage Benzoxazines - pharmacokinetics Child, Preschool Children Cohort Studies Coinfection - drug therapy Cytochrome P-450 CYP2B6 - genetics Dosage Efavirenz Female Genotype Genotype & phenotype Genotypes HIV HIV Infections - drug therapy Human immunodeficiency virus Humans India Infant Male Neutropenia Pharmacokinetics Pharmacology Prospective Studies Safety Treatment Outcome Tuberculosis Tuberculosis - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND:CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection. METHODS:Phase I, 24-week safety and pharmacokinetic (PK) study of EFV in HIV-infected children aged 3 to
ISSN:	1525-4135 1944-7884
DOI:	10.1097/QAI.0000000000002061